Abstract
Objective To investigate the feasibility of preparation of dentritic cell vaccine modified by adenovirus-mediated mouse interleukin (mIL)-15 gene and cell lysate on mouse with prostate cancer. Methods Dentritic cells (DCs) are modified by adenovirus-mediated mIL-15 gene and cell lysate on mouse with prostate cancer. The transduction efficiency and phenotypes of DCs were analyzed by flow cytometry (FCM). Results DCs are effectively infected by adenovirus-mediated mIL-15 gene with a transduction efficiency of (77.43±1.96)%, which is confirmed by FCM. After modified by adenovirus-mediated mIL-15 gene and cell lysate on mouse with prostate cancer, the expresson of surface molecules of DCs were up-regulated, inculding CD40 [(52.50±2.36)%], CD80 [(46.53±0.91)%], CD86 [(47.10±2.59)%], CD11c [(32.07±1.72)%] and major histocompatibility complex (MHC)-Ⅱ [(53.57±2.72)%]. Compared with control groups, the mIL-15/lysate DC vaccine can stimulate the proliferation of T cells more strongly. Conclusion The mIL-15/lysate DC vaccine has been successfully prepared and identified. Key words: Interleukin-15; Prostate cancer; Dentritic cell; Vaccine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
